Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Valuation and Earnings
This table compares Pasithea Therapeutics and Vericel”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pasithea Therapeutics | N/A | N/A | -$13.90 million | ($5.09) | -0.15 |
| Vericel | $276.26 million | 5.87 | $16.52 million | $0.31 | 102.68 |
Risk and Volatility
Pasithea Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.
Insider & Institutional Ownership
23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 7.2% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Pasithea Therapeutics and Vericel, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pasithea Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Vericel | 0 | 3 | 5 | 0 | 2.63 |
Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 282.65%. Vericel has a consensus target price of $56.00, indicating a potential upside of 75.93%. Given Pasithea Therapeutics’ higher possible upside, equities research analysts plainly believe Pasithea Therapeutics is more favorable than Vericel.
Profitability
This table compares Pasithea Therapeutics and Vericel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pasithea Therapeutics | N/A | -97.88% | -87.96% |
| Vericel | 5.98% | 5.17% | 3.67% |
Summary
Vericel beats Pasithea Therapeutics on 11 of the 13 factors compared between the two stocks.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
